{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:41:42Z","timestamp":1790516502364,"version":"4.1.0"},"reference-count":77,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2013,4,2]],"date-time":"2013-04-02T00:00:00Z","timestamp":1364860800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0060113","type":"journal-article","created":{"date-parts":[[2013,4,2]],"date-time":"2013-04-02T22:04:04Z","timestamp":1364940244000},"page":"e60113","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":47,"title":["SMA-MAP: A Plasma Protein Panel for Spinal Muscular Atrophy"],"prefix":"10.1371","volume":"8","author":[{"given":"Dione T.","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karri L.","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Dewey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mapes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Swoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Plasterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Biomarkers for Spinal Muscular Atrophy Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy K.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil T.","family":"Darras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Sproule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl C.","family":"De Vivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Pediatric Neuromuscular Clinical Research Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,4,2]]},"reference":[{"key":"ref1","first-page":"291","article-title":"Progress and promise: the current status of spinal muscular atrophy therapeutics","volume":"12","author":"JP Van Meerbeke","year":"2011","journal-title":"Discov Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e21296","DOI":"10.1371\/journal.pone.0021296","article-title":"SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy","volume":"6","author":"JT Kissel","year":"2011","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nmd.2003.11.006","article-title":"Pilot trial of phenylbutyrate in spinal muscular atrophy","volume":"14","author":"E Mercuri","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.nmd.2008.05.004","article-title":"Daily salbutamol in young patients with SMA type II","volume":"18","author":"M Pane","year":"2008","journal-title":"Neuromuscul Disord"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e5268","DOI":"10.1371\/journal.pone.0005268","article-title":"Phase II open label study of valproic acid in spinal muscular atrophy","volume":"4","author":"KJ Swoboda","year":"2009","journal-title":"PLoS One"},{"key":"ref6","first-page":"CD006282","article-title":"Drug treatment for spinal muscular atrophy types II and III","volume":"4","author":"RI Wadman","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","first-page":"CD006281","article-title":"Drug treatment for spinal muscular atrophy type I. Cochrane Database Syst Rev","volume":"4","author":"RI Wadman","year":"2012"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-510X(01)00632-3","article-title":"A placebo-controlled trial of gabapentin in spinal muscular atrophy","volume":"191","author":"RG Miller","year":"2001","journal-title":"J Neurol Sci"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"KJ Swoboda","year":"2010","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1090-3798(03)00060-6","article-title":"The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation","volume":"7","author":"M Main","year":"2003","journal-title":"Eur J Paediatr Neurol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/mus.10050","article-title":"Motor unit number estimation in infants and children with spinal muscular atrophy","volume":"25","author":"MB Bromberg","year":"2002","journal-title":"Muscle Nerve"},{"key":"ref12","article-title":"A methodology to measure the strength of SMA patients. Dallas-Cincinnati-Newington Spinal Muscular Atrophy (DCN-SMA) Study Group","volume":"13","author":"JD Cook","year":"1990","journal-title":"Muscle Nerve"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.nmd.2009.09.009","article-title":"The PedsQL in pediatric patients with Spinal Muscular Atrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Generic Core Scales and Neuromuscular Module","volume":"19","author":"ST Iannaccone","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/088307380001500207","article-title":"Prospective analysis of strength in spinal muscular atrophy. DCN\/Spinal Muscular Atrophy Group","volume":"15","author":"ST Iannaccone","year":"2000","journal-title":"J Child Neurol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/archneurol.2010.373","article-title":"Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year","volume":"68","author":"P Kaufmann","year":"2011","journal-title":"Arch Neurol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.nmd.2006.03.015","article-title":"A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy","volume":"16","author":"KJ Krosschell","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.21838","article-title":"Compound muscle action potential and motor function in children with spinal muscular atrophy","volume":"42","author":"A Lewelt","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.nmd.2006.03.005","article-title":"The gross motor function measure is a valid and sensitive outcome measure for spinal muscular atrophy","volume":"16","author":"L Nelson","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients","volume":"17","author":"JM O\u2019Hagen","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/088307389400900321","article-title":"Pulmonary function in spinal muscular atrophy","volume":"9","author":"FJ Samaha","year":"1994","journal-title":"J Child Neurol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/ijms12010024","article-title":"Biomarkers in rare disorders: the experience with spinal muscular atrophy","volume":"12","author":"FD Tiziano","year":"2010","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Kaufmann P, McDermott MP, Darras BT, Finkel RS, Sproule DM, et al.. (2012) Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology.","DOI":"10.1212\/WNL.0b013e318271f7e4"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/mus.21784","article-title":"Characterizing spinal muscular atrophy with electrical impedance myography","volume":"42","author":"SB Rutkove","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/0883073810380457","article-title":"Muscle volume estimation by magnetic resonance imaging in spinal muscular atrophy","volume":"26","author":"DM Sproule","year":"2011","journal-title":"J Child Neurol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e33572","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","author":"TO Crawford","year":"2012","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e35462","DOI":"10.1371\/journal.pone.0035462","article-title":"Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical study","volume":"7","author":"RS Finkel","year":"2012","journal-title":"PLoS One"},{"key":"ref27","unstructured":"Long JS (1997) Limited outcome: The Tobit model. Regression models for categorical and limited dependent variables: SAGE Publications. 187\u2013216."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Y Hua","year":"2011","journal-title":"Nature"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1093\/hmg\/ddr067","article-title":"Increased IGF-1 in muscle modulates the phenotype of severe SMA mice","volume":"20","author":"M Bosch-Marce","year":"2011","journal-title":"Hum Mol Genet"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Murdocca M, Malgieri A, Luchetti A, Saieva L, Dobrowolny G, et al.. (2012) IPLEX administration improves motor neuron survival and ameliorates motor functions in a severe mouse model of SMA. Mol Med.","DOI":"10.2119\/molmed.2012.00056"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/hum.2010.114","article-title":"Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy","volume":"22","author":"M Shababi","year":"2011","journal-title":"Hum Gene Ther"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1741-7015-7-14","article-title":"Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy","volume":"7","author":"C Millino","year":"2009","journal-title":"BMC Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"e50763","DOI":"10.1371\/journal.pone.0050763","article-title":"Evaluation of peripheral blood mononuclear cell processing and analysis for survival motor neuron protein","volume":"7","author":"DT Kobayashi","year":"2012","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Tiziano FD, Lomastro R, Di Pietro L, Barbara Pasanisi M, Fiori S, et al.. (2012) Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study. Eur J Hum Genet.","DOI":"10.1038\/ejhg.2012.233"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.23582","article-title":"Glucose metabolism and pancreatic defects in spinal muscular atrophy","volume":"72","author":"M Bowerman","year":"2012","journal-title":"Ann Neurol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/1531-8249(199903)45:3<337::AID-ANA9>3.0.CO;2-U","article-title":"Abnormal fatty acid metabolism in childhood spinal muscular atrophy","volume":"45","author":"TO Crawford","year":"1999","journal-title":"Ann Neurol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/hmg\/ddr453","article-title":"Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy","volume":"21","author":"KK Ling","year":"2012","journal-title":"Hum Mol Genet"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1093\/hmg\/ddr360","article-title":"Reversible molecular pathology of skeletal muscle in spinal muscular atrophy","volume":"20","author":"CA Mutsaers","year":"2011","journal-title":"Hum Mol Genet"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/dneu.20946","article-title":"Extracellular matrix functions during neuronal migration and lamination in the mammalian central nervous system","volume":"71","author":"SJ Franco","year":"2011","journal-title":"Dev Neurobiol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nrn1805","article-title":"Bone morphogenetic protein signalling and vertebrate nervous system development","volume":"6","author":"A Liu","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1021\/pr200695p","article-title":"Identification of a panel of novel serum osteoarthritis biomarkers","volume":"10","author":"P Fernandez-Puente","year":"2011","journal-title":"J Proteome Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ng0997-104","article-title":"Tenascin-X deficiency is associated with Ehlers-Danlos syndrome","volume":"17","author":"GH Burch","year":"1997","journal-title":"Nat Genet"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/joca.2000.0366","article-title":"Quantitative analysis of gene expression in human articular cartilage from normal and osteoarthritic joints","volume":"9","author":"I Martin","year":"2001","journal-title":"Osteoarthritis Cartilage"},{"key":"ref44","first-page":"410","article-title":"Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism","volume":"32","author":"G Xu","year":"2005","journal-title":"J Rheumatol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/path.2566","article-title":"Bone loss in survival motor neuron (Smn(\u2212\/\u2212) SMN2) genetic mouse model of spinal muscular atrophy","volume":"219","author":"S Shanmugarajan","year":"2009","journal-title":"J Pathol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/0883073807305664","article-title":"Congenital bone fractures in spinal muscular atrophy: functional role for SMN protein in bone remodeling","volume":"22","author":"S Shanmugarajan","year":"2007","journal-title":"J Child Neurol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4161\/isl.3.6.17705","article-title":"T-cadherin (Cdh13) in association with pancreatic beta-cell granules contributes to second phase insulin secretion","volume":"3","author":"B Tyrberg","year":"2011","journal-title":"Islets"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1592\/phco.30.5.463","article-title":"Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus","volume":"30","author":"JJ Neumiller","year":"2010","journal-title":"Pharmacotherapy"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrn2474","article-title":"The insulin paradox: aging, proteotoxicity and neurodegeneration","volume":"9","author":"E Cohen","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.nmd.2010.05.013","article-title":"Adiposity is increased among high-functioning, non-ambulatory patients with spinal muscular atrophy","volume":"20","author":"DM Sproule","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/0883073811415680","article-title":"Age at disease onset predicts likelihood and rapidity of growth failure among infants and young children with spinal muscular atrophy types 1 and 2","volume":"27","author":"DM Sproule","year":"2012","journal-title":"J Child Neurol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/aje\/kwi174","article-title":"Genetics of leptin and obesity: a HuGE review","volume":"162","author":"V Paracchini","year":"2005","journal-title":"Am J Epidemiol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.bbadis.2011.02.012","article-title":"ETS-domain transcription factor Elk-1 mediates neuronal survival: SMN as a potential target","volume":"1812","author":"O Demir","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/hmg\/ddq500","article-title":"HuD interacts with survival motor neuron protein and can rescue spinal muscular atrophy-like neuronal defects","volume":"20","author":"L Hubers","year":"2011","journal-title":"Hum Mol Genet"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"e24269","DOI":"10.1371\/journal.pone.0024269","article-title":"Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses","volume":"6","author":"DT Kobayashi","year":"2011","journal-title":"PLoS One"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"e3209","DOI":"10.1371\/journal.pone.0003209","article-title":"Modeling spinal muscular atrophy in Drosophila","volume":"3","author":"HC Chang","year":"2008","journal-title":"PLoS One"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"e1001172","DOI":"10.1371\/journal.pgen.1001172","article-title":"Conserved genes act as modifiers of invertebrate SMN loss of function defects","volume":"6","author":"M Dimitriadi","year":"2010","journal-title":"PLoS Genet"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nchembio.595","article-title":"A screen for regulators of survival of motor neuron protein levels","volume":"7","author":"NR Makhortova","year":"2011","journal-title":"Nat Chem Biol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1093\/hmg\/ddr425","article-title":"The spinal muscular atrophy disease protein SMN is linked to the Rho-kinase pathway via profilin","volume":"20","author":"A Nolle","year":"2011","journal-title":"Hum Mol Genet"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"e31202","DOI":"10.1371\/journal.pone.0031202","article-title":"Analysis of the fibroblast growth factor system reveals alterations in a mouse model of spinal muscular atrophy","volume":"7","author":"N Hensel","year":"2012","journal-title":"PLoS One"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"25782","DOI":"10.1074\/jbc.M112.362830","article-title":"Human Axonal Survival of Motor Neuron (a-SMN) Protein Stimulates Axon Growth, Cell Motility, C-C Motif Ligand 2 (CCL2), and Insulin-like Growth Factor-1 (IGF1) Production","volume":"287","author":"D Locatelli","year":"2012","journal-title":"J Biol Chem"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1172\/JCI46276","article-title":"Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway","volume":"121","author":"F Farooq","year":"2011","journal-title":"J Clin Invest"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/mus.21488","article-title":"Applying proteomics to the diagnosis and treatment of ALS and related diseases","volume":"40","author":"R Bowser","year":"2009","journal-title":"Muscle Nerve"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ana.22271","article-title":"Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease","volume":"69","author":"AS Chen-Plotkin","year":"2011","journal-title":"Ann Neurol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"15000","DOI":"10.1073\/pnas.192571199","article-title":"Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle","volume":"99","author":"JN Haslett","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1080\/00365510701604628","article-title":"Decreased serum endoglin level in patients with amyotrophic lateral sclerosis: a preliminary report","volume":"68","author":"J Ilzecka","year":"2008","journal-title":"Scand J Clin Lab Invest"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF03256203","article-title":"Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease","volume":"10","author":"C Kolarcik","year":"2006","journal-title":"Mol Diagn Ther"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/17482968.2011.619197","article-title":"Biochemical alterations associated with ALS","volume":"13","author":"KA Lawton","year":"2012","journal-title":"Amyotroph Lateral Scler"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"e25545","DOI":"10.1371\/journal.pone.0025545","article-title":"Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells","volume":"6","author":"G Nardo","year":"2011","journal-title":"PLoS One"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1586\/epr.10.2","article-title":"Proteomics of skeletal muscle differentiation, neuromuscular disorders and fiber aging","volume":"7","author":"K Ohlendieck","year":"2010","journal-title":"Expert Rev Proteomics"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1212\/WNL.0b013e318207afeb","article-title":"SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy","volume":"76","author":"E Pegoraro","year":"2011","journal-title":"Neurology"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/1471-2164-10-405","article-title":"Weighted gene co-expression network analysis of the peripheral blood from Amyotrophic Lateral Sclerosis patients","volume":"10","author":"CG Saris","year":"2009","journal-title":"BMC Genomics"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00702-003-0832-x","article-title":"Modulation of disease risk according to a cathepsin D\/apolipoprotein E genotype in Parkinson\u2019s disease","volume":"110","author":"T Schulte","year":"2003","journal-title":"J Neural Transm"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1749-6632.2009.05066.x","article-title":"Identifying early markers of Alzheimer\u2019s disease using quantitative multiplex proteomic immunoassay panels","volume":"1180","author":"HD Soares","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, et al.. (2012) Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease. Arch Neurol: 1\u20138.","DOI":"10.1001\/archneurol.2012.1070"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.0b013e3182604395","article-title":"Machine learning algorithms to classify spinal muscular atrophy subtypes","volume":"79","author":"T Srivastava","year":"2012","journal-title":"Neurology"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/npp.2011.177","article-title":"Neuroscience networking: linking discovery to drugs","volume":"37","author":"J Heemskerk","year":"2012","journal-title":"Neuropsychopharmacology"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0060113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T21:48:51Z","timestamp":1644702531000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0060113"}},"subtitle":[],"editor":[{"given":"Thomas H.","family":"Gillingwater","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,4,2]]},"references-count":77,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0060113","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,2]]}}}